Lv42
444 积分 2024-08-19 加入
MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
3小时前
待确认
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter study
7天前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
8天前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
14天前
已完结
Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancer
19天前
已完结
Optimizing adjuvant therapy under the guidance of MPR: A multicenter retrospective analysis of neoadjuvant therapy in non-small cell lung cancer
19天前
已关闭
STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer
23天前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
24天前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
25天前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
27天前
已完结
皖公网安备34019202002308
